Key Findings
- Across 50 randomized trials (8,857 participants), cranberry products were associated with a reduced risk of UTIs versus placebo, water, or no treatment (risk ratio 0.70).
- The clearest benefit was in women with recurrent UTIs (risk ratio about 0.53) and in children.
- Little or no benefit was seen in elderly people in institutions or during pregnancy, so effectiveness depends heavily on the population.
- Proanthocyanidin content (the proposed active compounds) varies between products, which may contribute to inconsistent results.